Novo Will Slash US List Prices for Wegovy, Ozempic Next Year (2)

Novo Nordisk A/S plans to slash the US list prices for its blockbusters Wegovy and Ozempic next year as the drugmaker struggles to claw back a larger share of the obesity market.

The Danish drugmaker set a monthly price of $675 across the board for its semaglutide family of medicines, a cut of as much as 50%. Zepbound, Eli Lilly & Co.’s competing obesity drug, currently has a list price of $1,086.37.

It’s not clear yet what the impact of the change will have on Novo’s bottom line. In highly competitive categories, drugmakers typically provide heavy discounts off the ...